Jun 2026 (Q2 FY26) — Aug 12, 2026
Spero Therapeutics Q2 FY26 — FDA Approval, Pipeline Repositioning, and Strategic Financing
Read the full callSpero Therapeutics (SPRO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Spero Therapeutics earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.00 | −100.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -9.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.12 +1.82% · +$0.02
Performance −49.3% 1Y
1Y: $2.21 on 17 Oct 2025 → $1.12. High $2.98 (4 Jun 2026), low $1.1 (16 Oct 2026).
- Previous close
- $1.1
- 52-week range
- $1.1 – $2.98
- One year
- −51.09%
Overview
- Symbol
- SPRO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Spero Therapeutics earnings calls (SPRO)
Financials
What the filings say
Net profit, year on year: −462% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 15 | 6 | 14 | 5 | 41 | 0 | 0 |
| Operating profit | -19 | -22 | -15 | -2 | -8 | 31 | -8 | -10 |
| Operating margin | −138.0% | −144.4% | −250.8% | −17.2% | −145.5% | 76.0% | −2921.7% | — |
| Other income | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Net profit | -17 | -21 | -14 | -2 | -7 | 32 | -7 | -10 |
| EPS ($ per share) | -0.32 | — | -0.25 | -0.03 | -0.13 | — | -0.13 | -0.16 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -139 | -199 | -278 | -367 | -414 | -391 | -460 | -451 |
| Total liabilities | 13 | 32 | 21 | 83 | 49 | 75 | 64 | 10 |
| Fixed assets | 3 | 2 | 2 | 1 | 0 | 0 | 0 | — |
| Investments | 81 | 52 | 42 | 34 | 0 | — | — | — |
| Total assets | 129 | 106 | 153 | 171 | 125 | 182 | 111 | 69 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -40 | -50 | -86 | -64 | -8 | -33 | -23 | -13 |
| Cash from investing | -83 | 30 | 10 | 8 | 34 | 0 | — | — |
| Cash from financing | 70 | 16 | 131 | 84 | -30 | 0 | 0 | — |
| Net cash flow | -53 | -4 | 55 | 27 | -3 | -33 | -23 | -13 |
| Capital expenditure | -2 | -0 | -0 | — | — | — | — | — |
| Free cash flow | -42 | -50 | -86 | — | — | — | — | — |
Insider filings
19 filings between Nov 7, 2025 and Aug 3, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$552.0K
9 sales by 2 insiders
Compensation
not trading decisions- 10
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Rajavelu Esther | — | $406.8K | May 4, 2026 |
| Keutzer Timothy | — | $145.2K | Feb 6, 2026 |
Latest filings (44)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 3, 2026 | Zack Debra Chief Medical Officer | Award 10b5-1 plan | 162,311 | $0 |
| Jun 23, 2026 | Pottage John C Jr Director | Award | 10,000 | $0 |
| Jun 23, 2026 | THOMAS FRANK E Director | Award | 10,000 | $0 |
| Jun 23, 2026 | VINK PATRICK V.J.J. Director | Award | 10,000 | $0 |
| Jun 23, 2026 | Smith Cynthia Director | Award | 10,000 | $0 |
| Jun 23, 2026 | Tregoning Kathleen Director | Award | 10,000 | $0 |
| Jun 23, 2026 | Deshpande Milind Director | Award | 10,000 | $0 |
| Jun 23, 2026 | Jackson Scott Thomas Director | Award | 10,000 | $0 |
| May 4, 2026 | Rajavelu Esther See Remarks | Sale | 25,240 | $63.4K |
| Feb 6, 2026 | Rajavelu Esther See Remarks | Sale | 37,101 | $87.6K |
| Feb 6, 2026 | Keutzer Timothy Chief Operating Officer | Sale | 18,652 | $44.0K |
| Feb 6, 2026 | Rajavelu Esther See Remarks | Sale | 50,816 | $119.9K |
| Feb 4, 2026 | Keutzer Timothy Chief Operating Officer | Sale | 3,471 | $7.8K |
| Feb 3, 2026 | Keutzer Timothy Chief Operating Officer | Sale | 24,224 | $51.8K |
| Feb 2, 2026 | Keutzer Timothy Chief Operating Officer | Award | 68,000 | $0 |
| Feb 2, 2026 | Keutzer Timothy Chief Operating Officer | Sale | 18,891 | $41.6K |
| Feb 2, 2026 | Rajavelu Esther See Remarks | Award | 249,000 | $0 |
| Feb 2, 2026 | Rajavelu Esther See Remarks | Sale | 18,442 | $40.6K |
| Nov 7, 2025 | Rajavelu Esther See Remarks | Sale | 40,270 | $95.4K |
| Aug 28, 2025 | Mahadevia Ankit Director | Sale | 6,572 | $12.9K |
| Jun 12, 2025 | Mahadevia Ankit Director | Award | 20,000 | $0 |
| Jun 12, 2025 | Tregoning Kathleen Director | Award | 20,000 | $0 |
| Jun 12, 2025 | THOMAS FRANK E Director | Award | 20,000 | $0 |
| Jun 12, 2025 | Smith Cynthia Director | Award | 20,000 | $0 |
| Jun 12, 2025 | Pottage John C Jr Director | Award | 20,000 | $0 |
| Jun 12, 2025 | VINK PATRICK V.J.J. Director | Award | 20,000 | $0 |
| Jun 12, 2025 | Jackson Scott Thomas Director | Award | 20,000 | $0 |
| Jun 12, 2025 | Deshpande Milind Director | Award | 20,000 | $0 |
| May 2, 2025 | Rajavelu Esther See Remarks | Award | 185,000 | $0 |
| Feb 5, 2025 | Keutzer Timothy Chief Operating Officer | Sale | 3,974 | $3.1K |
| Feb 5, 2025 | Keutzer Timothy Chief Operating Officer | Sale | 27,643 | $21.6K |
| Feb 5, 2025 | Keutzer Timothy Chief Operating Officer | Sale | 24,920 | $19.4K |
| Feb 5, 2025 | Shukla Sath CEO & President | Sale | 6,139 | $4.8K |
| Feb 5, 2025 | Shukla Sath CEO & President | Sale | 42,786 | $33.4K |
| Feb 5, 2025 | Shukla Sath CEO & President | Sale | 106,408 | $83.0K |
| Feb 5, 2025 | Mahadevia Ankit Director | Sale | 55,260 | $43.1K |
| Feb 5, 2025 | Mahadevia Ankit Director | Sale | 13,959 | $10.9K |
| Feb 5, 2025 | Rajavelu Esther CFO & CBO | Sale | 20,689 | $16.1K |
| Feb 3, 2025 | Rajavelu Esther CFO & CBO | Award | 100,000 | $0 |
| Feb 3, 2025 | Shukla Sath CEO & President | Award | 751,407 | $0 |
| Feb 3, 2025 | Rajavelu Esther CFO & CBO | Award | 266,139 | $0 |
| Feb 3, 2025 | Keutzer Timothy Chief Operating Officer | Award | 266,139 | $0 |
| Nov 8, 2024 | Rajavelu Esther CFO & CBO | Sale | 17,245 | $22.4K |
| Nov 7, 2024 | Rajavelu Esther CFO & CBO | Sale | 23,351 | $30.6K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Spero Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Spero Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading